Payment overview · 2025
General Payments
$532.72
20 reported records · 11 companies
Healthcare provider profile · identity verified
Alyson Demitraszek, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · NISKAYUNA, NY · NPI 1205562899
Verified facts
What the public records show
CMS Open Payments records show Alyson Demitraszek, NP received $532.72 in general payments during 2025 across 20 reported records.
Janssen Biotech, Inc. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $158.07 | 29.7% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $66.29 | 12.4% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $55.55 | 10.4% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $54.54 | 10.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $54.23 | 10.2% | 2 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $32.64 | 6.1% | 1 | 2025 |
| AVYXA PHARMA, LLC | Unresolved — no canonical attribution shown | $31.73 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.18 | 4.5% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $19.34 | 3.6% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $19.23 | 3.6% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.92 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.73 | 19 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $158.07 | 4 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $55.55 | 3 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $54.54 | 2 | 2025 |
Source payment records
|
|||||
| Padcev Normalized: padcev |
Drug | Astellas Pharma US Inc | $54.23 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $44.68 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeiGene USA, Inc. | $32.64 | 1 | 2025 |
Source payment records
|
|||||
| AXTLE Normalized: axtle |
Drug | AVYXA PHARMA, LLC | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| DOCIVYX Normalized: docivyx |
Drug | AVYXA PHARMA, LLC | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| FRINDOVYX Normalized: frindovyx |
Drug | AVYXA PHARMA, LLC | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| LUTRATE DEPOT Normalized: lutrate depot |
Drug | AVYXA PHARMA, LLC | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| POSFREA Normalized: posfrea |
Drug | AVYXA PHARMA, LLC | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 679 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 49 |
| Lisinopril | Lisinopril | 412 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 28 |
| Metformin Hcl | Metformin Hcl | 298 | 30 |
| Simvastatin | Simvastatin | 243 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 23 |
| Omeprazole | Omeprazole | 187 | 31 |
| Finasteride | Finasteride | 128 | 11 |
| Alendronate Sodium | Alendronate Sodium | 127 | 16 |
| Famotidine | Famotidine | 109 | 16 |
| Baclofen | Baclofen | 104 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 99 | suppressed |
| Lamotrigine | Lamotrigine | 89 | suppressed |
| Losartan Potassium | Losartan Potassium | 88 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 86 | suppressed |
| Furosemide | Furosemide | 85 | suppressed |
| Linzess | Linaclotide | 83 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 83 | 12 |
| Montelukast Sodium | Montelukast Sodium | 80 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 24 |
| Januvia | Sitagliptin Phosphate | 67 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 67 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 66 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 17 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Spironolactone | Spironolactone | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Lactulose | Lactulose | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Trimethoprim | Trimethoprim | 34 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Gabapentin | Gabapentin | 30 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 23 | suppressed |
| Enulose | Lactulose | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Prolia | Denosumab | 15 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | 12 |
| Nadolol | Nadolol | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $532.72 · 20 records | Janssen Biotech, Inc. | AXTLE, BRUKINSA, CABOMETYX, CARVYKTI, DOCIVYX, ELAHERE, Enhertu, FRINDOVYX, JAKAFI, LIBTAYO, LUTRATE DEPOT, MONJUVI, POSFREA, PYRUKYND, Padcev, REBLOZYL, RYBREVANT, ZYNYZ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error